Picture loading failed.

Pre-Made Abelacimab biosimilar, Whole mAb, Anti-F11 Antibody: Anti-FXI/PTA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Abelacimab (previously known as MAA 868) is a fully human, factor XI monoclonal antibody, being developed by Anthos Therapeutics under the license from Novartis, for the prevention of cardiovascular disorders including stroke due to thrombosis and thromboembolism in patients with atrial fibrillation.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-002-1mg 1mg 3090
GMP-Bios-ab-002-10mg 10mg 21890
GMP-Bios-ab-002-100mg 100mg 148000
GMP-Bios-ab-002-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Abelacimab biosimilar, Whole mAb, Anti-F11 Antibody: Anti-FXI/PTA therapeutic antibody
INN Name Abelacimab
TargetF11 mRNA
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI Structure6r8x:CB
Year Proposed2018
Year Recommended2019
CompaniesNovartis
Conditions Approvedna
Conditions ActiveVenous Thromboembolism; Stroke;Thrombosis
Conditions Discontinuedna
Development Techna